On the public citation graph

Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma

0 signed · 157 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2019.11642openalex-snapshot
Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma
inferredcites →https://doi.org/10.1002/cncr.22132openalex-snapshot
Telomere length is a prognostic factor in neuroblastoma
inferredcites →https://doi.org/10.1002/cncr.30934openalex-snapshot
Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials
inferredcites →https://doi.org/10.1002/gcc.20850openalex-snapshot
Alternative lengthening of telomeres—An enhanced chromosomal instability in aggressive non‐MYCN amplified and telomere elongated neuroblastomas
inferredcites →https://doi.org/10.1002/pbc.22693openalex-snapshot
Treatment and outcomes of patients with relapsed, high‐risk neuroblastoma: Results of German trials
inferredcites →https://doi.org/10.1002/pbc.25359openalex-snapshot
Going back to class I: MHC and immunotherapies for childhood cancer
inferredcites →https://doi.org/10.1002/pbc.26192openalex-snapshot
Outcome of children with relapsed or refractory neuroblastoma: A meta‐analysis of ITCC/SIOPEN European phase II clinical trials
inferredcites →https://doi.org/10.1002/pbc.26334openalex-snapshot
Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature
inferredcites →https://doi.org/10.1007/s11060-016-2189-7openalex-snapshot
A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study
inferredcites →https://doi.org/10.1007/s12094-006-0114-9openalex-snapshot
Advances in neuroblastoma research
inferredcites →https://doi.org/10.1016/j.ccell.2017.08.003openalex-snapshot
Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma
inferredcites →https://doi.org/10.1016/j.cell.2012.03.043openalex-snapshot
Cyclin F-Mediated Degradation of Ribonucleotide Reductase M2 Controls Genome Integrity and DNA Repair
inferredcites →https://doi.org/10.1016/j.cell.2014.10.024openalex-snapshot
CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer
inferredcites →https://doi.org/10.1016/j.celrep.2017.11.090openalex-snapshot
Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle
inferredcites →https://doi.org/10.1016/j.chembiol.2017.11.007openalex-snapshot
Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors
inferredcites →https://doi.org/10.1016/j.ejca.2012.01.037openalex-snapshot
Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth
inferredcites →https://doi.org/10.1016/j.ejca.2014.10.029openalex-snapshot
Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer
inferredcites →https://doi.org/10.1016/j.ejca.2016.04.001openalex-snapshot
Implementation of mechanism of action biology-driven early drug development for children with cancer
inferredcites →https://doi.org/10.1016/j.ejca.2019.01.013openalex-snapshot
ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children
inferredcites →https://doi.org/10.1016/j.mrfmmm.2016.02.003openalex-snapshot
FANCJ at the FORK
inferredcites →https://doi.org/10.1016/s1470-2045(13)70309-7openalex-snapshot
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(17)30070-0openalex-snapshot
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(17)30355-8openalex-snapshot
Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(18)30105-0openalex-snapshot
10-year report on the European Paediatric Regulation and its impact on new drugs for children's cancers
inferredcites →https://doi.org/10.1016/s1470-2045(18)30578-3openalex-snapshot
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(19)30671-0openalex-snapshot
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(19)30693-xopenalex-snapshot
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study
inferredcites →https://doi.org/10.1038/bjc.2016.302openalex-snapshot
Factors associated with recurrence and survival length following relapse in patients with neuroblastoma
inferredcites →https://doi.org/10.1038/nature10334openalex-snapshot
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
inferredcites →https://doi.org/10.1038/nature14980openalex-snapshot
Telomerase activation by genomic rearrangements in high-risk neuroblastoma
inferredcites →https://doi.org/10.1038/nature25480openalex-snapshot
The landscape of genomic alterations across childhood cancers
inferredcites →https://doi.org/10.1038/ng.3333openalex-snapshot
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
inferredcites →https://doi.org/10.1038/ng.3438openalex-snapshot
TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors
inferredcites →https://doi.org/10.1038/ng1627openalex-snapshot
The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair
inferredcites →https://doi.org/10.1038/nrd4553openalex-snapshot
Exploiting replicative stress to treat cancer
inferredcites →https://doi.org/10.1038/onc.2017.40openalex-snapshot
PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma
inferredcites →https://doi.org/10.1038/s41467-018-06699-9openalex-snapshot
TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets
inferredcites →https://doi.org/10.1038/s41598-018-32659-wopenalex-snapshot
Maintenance DFMO Increases Survival in High Risk Neuroblastoma
inferredcites →https://doi.org/10.1038/s41598-018-35868-5openalex-snapshot
In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors
inferredcites →https://doi.org/10.1038/sj.onc.1205145openalex-snapshot
c-Myc initiates illegitimate replication of the ribonucleotide reductase R2 gene
inferredcites →https://doi.org/10.1056/nejm198510313131802openalex-snapshot
Association of Multiple Copies of the N- myc Oncogene with Rapid Progression of Neuroblastomas
inferredcites →https://doi.org/10.1056/nejmoa0911123openalex-snapshot
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
inferredcites →https://doi.org/10.1073/pnas.1012351108openalex-snapshot
RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma
inferredcites →https://doi.org/10.1073/pnas.1610626113openalex-snapshot
Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors
inferredcites →https://doi.org/10.1080/17460441.2017.1340269openalex-snapshot
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project
inferredcites →https://doi.org/10.1080/2162402x.2018.1461305openalex-snapshot
Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study
inferredcites →https://doi.org/10.1093/jnci/djw274openalex-snapshot
Target and Agent Prioritization for the Children’s Oncology Group—National Cancer Institute Pediatric MATCH Trial
inferredcites →https://doi.org/10.1093/jnci/djx061openalex-snapshot
A Cisplatin Derivative Tetra-Pt(bpy) as an Oncotherapeutic Agent for Targeting ALT Cancer
inferredcites →https://doi.org/10.1126/science.1257216openalex-snapshot
Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors
inferredcites →https://doi.org/10.1126/science.aat6768openalex-snapshot
A mechanistic classification of clinical phenotypes in neuroblastoma
inferredcites →https://doi.org/10.1126/scitranslmed.aau1099openalex-snapshot
Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma
inferredcites →https://doi.org/10.1146/annurev-pathol-012414-040424openalex-snapshot
DNA Replication Stress as a Hallmark of Cancer
inferredcites →https://doi.org/10.1158/0008-5472.can-12-2669openalex-snapshot
Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in Neuroblastoma
inferredcites →https://doi.org/10.1158/0008-5472.can-14-3443openalex-snapshot
Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity
inferredcites →https://doi.org/10.1158/0008-5472.can-19-0008openalex-snapshot
A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma
inferredcites →https://doi.org/10.1158/1078-0432.ccr-12-1322openalex-snapshot
CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs
inferredcites →https://doi.org/10.1158/1078-0432.ccr-13-1117openalex-snapshot
A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Study (ADVL1112)
inferredcites →https://doi.org/10.1158/1078-0432.ccr-14-1592openalex-snapshot
A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study
inferredcites →https://doi.org/10.1158/1078-0432.ccr-15-1449openalex-snapshot
Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
inferredcites →https://doi.org/10.1158/1078-0432.ccr-16-1114openalex-snapshot
Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
inferredcites →https://doi.org/10.1158/1078-0432.ccr-16-2898openalex-snapshot
A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors
inferredcites →https://doi.org/10.1158/1078-0432.ccr-17-0379openalex-snapshot
A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma
inferredcites →https://doi.org/10.1158/1078-0432.ccr-18-1317openalex-snapshot
Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma
inferredcites →https://doi.org/10.1158/1078-0432.ccr-18-1381openalex-snapshot
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
inferredcites →https://doi.org/10.1158/1078-0432.ccr-19-1452openalex-snapshot
A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma
inferredcites →https://doi.org/10.1158/1535-7163.mct-18-0529openalex-snapshot
Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy
inferredcites →https://doi.org/10.1158/1538-7445.am2017-ct004openalex-snapshot
Abstract CT004: European pediatric precision medicine program in recurrent tumors: first results from MAPPYACTS molecular profiling trial towards AcSe-ESMART proof-of-concept study
inferredcites →https://doi.org/10.1158/2159-8290.cd-12-0418openalex-snapshot
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
inferredcites →https://doi.org/10.1158/2159-8290.cd-14-0609openalex-snapshot
Induction of Telomere Dysfunction Mediated by the Telomerase Substrate Precursor 6-Thio-2′-Deoxyguanosine
inferredcites →https://doi.org/10.1158/2159-8290.cd-15-1056openalex-snapshot
The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma
inferredcites →https://doi.org/10.1200/jco.2010.34.3392openalex-snapshot
Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project
inferredcites →https://doi.org/10.1200/jco.2015.65.4889openalex-snapshot
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial
inferredcites →https://doi.org/10.1200/jco.2017.35.15_suppl.10534openalex-snapshot
Early response rates and Curie scores at end of induction: An update from a phase II study of an anti-GD2 monoclonal antibody (mAb) with chemotherapy (CT) in newly diagnosed patients (pts) with high-risk (HR) neuroblastoma (NB).
inferredcites →https://doi.org/10.1242/dmm.024448openalex-snapshot
The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
inferredcites →https://doi.org/10.1371/journal.pone.0072967openalex-snapshot
BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models
inferredcites →https://doi.org/10.1593/neo.04316openalex-snapshot
Downregulation and/or Release of NKG2D Ligands as Immune Evasion Strategy of Human Neuroblastoma
inferredcites →https://doi.org/10.18632/oncotarget.10544openalex-snapshot
Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors
inferredcites →https://doi.org/10.18632/oncotarget.8547openalex-snapshot
High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition
inferredcites →https://doi.org/10.2174/13894501113149990194openalex-snapshot
MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance
inferredcites →https://doi.org/10.2217/fon-2018-0121openalex-snapshot
Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed/Refractory Malignancies
inferredcites →https://doi.org/10.2217/fon.11.87openalex-snapshot
Genetic Stratification of Neuroblastoma for Treatment Tailoring
inferredcites →https://doi.org/10.3109/15513815.2012.754527openalex-snapshot
The immune environment of paediatric solid malignancies: evidence from an immunohistochemical study of clinical cases
inferredcites →https://doi.org/10.3389/fonc.2016.00186openalex-snapshot
Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition
inferredcites →https://doi.org/10.3978/j.issn.2224-4336.2015.04.06openalex-snapshot
Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma.

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4834038openalex-extracted
Molecular Subtypes of Amino Acid Metabolism-Related Genes Predicting Prognosis, Tumor Microenvironment Composition, and Therapeutic Response in Neuroblastoma
inferred← citeshttps://doi.org/10.1002/cncr.35751openalex-snapshot
A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma
inferred← citeshttps://doi.org/10.1002/ctd2.237openalex-snapshot
The potential molecularly therapy target to MYCN‐amplificated neuroblastoma
inferred← citeshttps://doi.org/10.1002/pbc.30106openalex-snapshot
Systematic review of clinical drug development activities for neuroblastoma from 2011 to 2020
inferred← citeshttps://doi.org/10.1002/pbc.31176openalex-snapshot
Higher tumor mutational burden is associated with inferior outcomes among pediatric patients with neuroblastoma
inferred← citeshttps://doi.org/10.1002/pbc.31831openalex-snapshot
Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum
inferred← citeshttps://doi.org/10.1007/978-1-0716-2513-2_6openalex-snapshot
Establishment of In Vivo Acquired Resistance to Chemotherapy Via Individual Dose Escalation Treatment Regime
inferred← citeshttps://doi.org/10.1007/978-3-642-41168-7_193-2openalex-snapshot
Neuroblastome in der pädiatrischen Urologie
inferred← citeshttps://doi.org/10.1007/978-3-662-63400-4_193openalex-snapshot
Neuroblastome in der pädiatrischen Urologie
inferred← citeshttps://doi.org/10.1007/s00210-025-03865-xopenalex-snapshot
Combining network pharmacology and RNA sequencing to reveal the mechanism of emodin for the treatment of human neuroblastoma
inferred← citeshttps://doi.org/10.1007/s00280-021-04309-yopenalex-snapshot
Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma
inferred← citeshttps://doi.org/10.1007/s00428-025-04083-9openalex-snapshot
Peripheral neuroblastic tumors behaving badly: an update on high-risk morphologic and molecular groupings
inferred← citeshttps://doi.org/10.1007/s11523-025-01186-wopenalex-snapshot
Idasanutlin in Combination with Chemotherapy or Venetoclax in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors (iMATRIX Idasa): Results of a Phase I/II, Multicenter, Multi-arm Study
inferred← citeshttps://doi.org/10.1007/s12672-025-01975-9openalex-snapshot
Study of an N6-methyladenosine- and ferroptosis-related prognostic model and the mechanisms underlying the molecular network in neuroblastoma based on multiple datasets
inferred← citeshttps://doi.org/10.1016/bs.mie.2025.01.036openalex-snapshot
Novel LC-MS/MS assay to quantify D,L-alpha-difluoromethylornithine (DFMO) in mouse plasma
inferred← citeshttps://doi.org/10.1016/j.apmt.2022.101410openalex-snapshot
Conotoxin-derived biomimetic coiled cone-shaped peptide as ligand for selective nanodelivery to norepinephrine transporter-expressing neuroblastoma cells
inferred← citeshttps://doi.org/10.1016/j.bmc.2022.117043openalex-snapshot
Multiple approaches to repurposing drugs for neuroblastoma
inferred← citeshttps://doi.org/10.1016/j.cmpb.2023.107742openalex-snapshot
A multiscale orchestrated computational framework to reveal emergent phenomena in neuroblastoma
inferred← citeshttps://doi.org/10.1016/j.ejca.2020.10.009openalex-snapshot
Combined targeting of the p53 and pRb pathway in neuroblastoma does not lead to synergistic responses
inferred← citeshttps://doi.org/10.1016/j.ejca.2024.113923openalex-snapshot
Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS
inferred← citeshttps://doi.org/10.1016/j.ejca.2025.115275openalex-snapshot
Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicine
inferred← citeshttps://doi.org/10.1016/j.ejca.2026.116254openalex-snapshot
Current treatment strategies for first relapse of high-risk neuroblastoma
inferred← citeshttps://doi.org/10.1016/j.ejcped.2024.100177openalex-snapshot
DNA repair and replicative stress addiction in neuroblastoma
inferred← citeshttps://doi.org/10.1016/j.lungcan.2022.07.010openalex-snapshot
Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC
inferred← citeshttps://doi.org/10.1016/j.mtbio.2026.103164openalex-snapshot
A vitronectin-functionalized ECM-mimetic hydrogel platform for modelling integrin-dependent tumour responses to cilengitide
inferred← citeshttps://doi.org/10.1016/j.omtn.2021.08.021openalex-snapshot
A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics
inferred← citeshttps://doi.org/10.1016/j.paed.2022.02.001openalex-snapshot
Neuroblastoma: a master of disguise and a challenge to cure
inferred← citeshttps://doi.org/10.1016/j.patol.2024.100790openalex-snapshot
High-risk neuroblastoma: ATRX and TERT as prognostic markers and therapeutic targets. Review and update on the topic
inferred← citeshttps://doi.org/10.1021/acs.jproteome.4c00554openalex-snapshot
Amino Acid Metabolism Subtypes in Neuroblastoma Identifying Distinct Prognosis and Therapeutic Vulnerabilities
inferred← citeshttps://doi.org/10.1038/s41392-024-01767-7openalex-snapshot
The two sides of chromosomal instability: drivers and brakes in cancer
inferred← citeshttps://doi.org/10.1038/s41416-022-01755-0openalex-snapshot
Cellular senescence in neuroblastoma
inferred← citeshttps://doi.org/10.1038/s41416-024-02599-6openalex-snapshot
Approval of DFMO for high-risk neuroblastoma patients demonstrates a step of success to target MYC pathway
inferred← citeshttps://doi.org/10.1038/s41416-026-03569-wopenalex-snapshot
A functional landscape for chromosome 17q in neuroblastoma: balancing replication stress and genomic stability
inferred← citeshttps://doi.org/10.1038/s41467-021-26640-xopenalex-snapshot
The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma
inferred← citeshttps://doi.org/10.1038/s41467-021-27057-2openalex-snapshot
ATR inhibition enables complete tumour regression in ALK-driven NB mouse models
inferred← citeshttps://doi.org/10.1038/s41467-023-43134-0openalex-snapshot
A CRISPR-drug perturbational map for identifying compounds to combine with commonly used chemotherapeutics
inferred← citeshttps://doi.org/10.1038/s41598-026-38123-4openalex-snapshot
CDK2 inhibition promotes neuronal differentiation in neuroblastoma
inferred← citeshttps://doi.org/10.1055/s-0045-1807243openalex-snapshot
Exploring Pediatric Neuroblastoma: A Comprehensive Analysis of Adrenal and Nonadrenal Tumor Characteristics in the United States
inferred← citeshttps://doi.org/10.1101/2022.11.10.515290openalex-snapshot
Elimusertib outperforms standard of care chemotherapy in preclinical patient-derived pediatric solid tumor models
inferred← citeshttps://doi.org/10.1101/2025.02.15.638336openalex-snapshot
A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma
inferred← citeshttps://doi.org/10.1158/1535-7163.mct-23-0094openalex-snapshot
Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
inferred← citeshttps://doi.org/10.1177/10732748231178177openalex-snapshot
Integrating Bulk-seq and Single-cell-seq Reveals Estrogen and MAPK Pathways Associating with Neuroblastoma Outcome
inferred← citeshttps://doi.org/10.1177/18758592241306263openalex-snapshot
Machine learning reveals the role of telomerase activation-related genes in the prognosis of neuroblastoma
inferred← citeshttps://doi.org/10.1186/s13045-022-01337-wopenalex-snapshot
Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma tumor cells
inferred← citeshttps://doi.org/10.1186/s13059-024-03309-4openalex-snapshot
An integrated single-cell RNA-seq map of human neuroblastoma tumors and preclinical models uncovers divergent mesenchymal-like gene expression programs
inferred← citeshttps://doi.org/10.1200/edbk_349783openalex-snapshot
High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes
inferred← citeshttps://doi.org/10.1200/jco.24.00546openalex-snapshot
US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy
inferred← citeshttps://doi.org/10.1208/s12249-025-03190-9openalex-snapshot
Integration of Design of Experiments for the Development and Evaluation of Sulfasalazine Loaded Hybrid Albumin Chitosan Based Polymeric Nanocarriers
inferred← citeshttps://doi.org/10.12677/acm.2023.132232openalex-snapshot
Research Progress of Telomere Maintenance in the Pathogenesis of Neuroblastoma
inferred← citeshttps://doi.org/10.1371/journal.pcbi.1012648openalex-snapshot
Multicellular model of neuroblastoma proposes unconventional therapy based on multiple roles of p53
inferred← citeshttps://doi.org/10.1371/journal.pone.0313939openalex-snapshot
Validation of the biological function and prognostic significance of AURKA in neuroblastoma
inferred← citeshttps://doi.org/10.19723/j.issn.1671-167x.2024.03.017openalex-snapshot
[Role and mechanism of cysteine and glycine-rich protein 2 in the malignant progression of neuroblastoma].
inferred← citeshttps://doi.org/10.21037/tcr-24-269openalex-snapshot
Identification of a ferroptosis-related gene signature for the prognosis of pediatric neuroblastoma
inferred← citeshttps://doi.org/10.21203/rs.3.rs-3356993/v1openalex-snapshot
Novel biomarkers involved in neuroblastoma revealed by integrative analysis of GEO data
inferred← citeshttps://doi.org/10.21203/rs.3.rs-4173002/v1openalex-snapshot
Three Novel Neuroblastoma Biomarkers Revealed by Integrative Analysis of GEO data
inferred← citeshttps://doi.org/10.33540/1328openalex-snapshot
Embryonic origin and treatment of disseminated neuroblastoma
inferred← citeshttps://doi.org/10.33696/signaling.7.148openalex-snapshot
Harnessing the Immune Arsenal against Neuroblastoma
inferred← citeshttps://doi.org/10.3389/fcell.2021.731380openalex-snapshot
Identification of an Autophagy-Related Risk Signature Correlates With Immunophenotype and Predicts Immune Checkpoint Blockade Efficacy of Neuroblastoma
inferred← citeshttps://doi.org/10.3389/fcell.2021.811297openalex-snapshot
Protein Tyrosine Phosphatases in Neuroblastoma: Emerging Roles as Biomarkers and Therapeutic Targets
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1853357openalex-snapshot
Identification of a novel PANoptosis-associated prognostic signature and immune landscape analysis in neuroblastoma with experimental validation
inferred← citeshttps://doi.org/10.3389/fmed.2023.1113460openalex-snapshot
Target therapy for high-risk neuroblastoma treatment: integration of regulatory and scientific tools is needed
inferred← citeshttps://doi.org/10.3389/fonc.2022.1085270openalex-snapshot
Patient-derived models: Advanced tools for precision medicine in neuroblastoma
inferred← citeshttps://doi.org/10.3389/fonc.2023.1235947openalex-snapshot
Pediatric oncology drug development and dosage optimization
inferred← citeshttps://doi.org/10.3389/fphar.2023.1162563openalex-snapshot
Integrative analysis of multi-omics data for discovery of ferroptosis-related gene signature predicting immune activity in neuroblastoma
inferred← citeshttps://doi.org/10.3390/cancers13174324openalex-snapshot
The Landscape of Pediatric Precision Oncology: Program Design, Actionable Alterations, and Clinical Trial Development
inferred← citeshttps://doi.org/10.3390/cells10081950openalex-snapshot
Enzymatic Spermine Metabolites Induce Apoptosis Associated with Increase of p53, caspase-3 and miR-34a in Both Neuroblastoma Cells, SJNKP and the N-Myc-Amplified Form IMR5
inferred← citeshttps://doi.org/10.3390/cells12222593openalex-snapshot
CRISPR-Cas System Is an Effective Tool for Identifying Drug Combinations That Provide Synergistic Therapeutic Potential in Cancers
inferred← citeshttps://doi.org/10.3390/ijms231911236openalex-snapshot
Italian Precision Medicine in Pediatric Oncology: Moving beyond Actionable Alterations
inferred← citeshttps://doi.org/10.3390/ijms241915027openalex-snapshot
Imidazo-Pyrazole-Loaded Palmitic Acid and Polystyrene-Based Nanoparticles: Synthesis, Characterization and Antiproliferative Activity on Chemo-Resistant Human Neuroblastoma Cells
inferred← citeshttps://doi.org/10.3390/jpm11040248openalex-snapshot
The Promise of Patient-Derived Preclinical Models to Accelerate the Implementation of Personalised Medicine for Children with Neuroblastoma
inferred← citeshttps://doi.org/10.3390/molecules26237069openalex-snapshot
Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma
inferred← citeshttps://doi.org/10.6084/m9.figshare.26066050openalex-snapshot
Additional file 1 of An integrated single-cell RNA-seq map of human neuroblastoma tumors and preclinical models uncovers divergent mesenchymal-like gene expression programs
inferred← citeshttps://doi.org/10.6084/m9.figshare.26066206openalex-snapshot
Additional file 2 of An integrated single-cell RNA-seq map of human neuroblastoma tumors and preclinical models uncovers divergent mesenchymal-like gene expression programs
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.